PGX-0100
AXP000239.1 · Phage therapy
- Platform
- phage cocktail spray
- Originator
- Precisio Biotix Therapeutics
- Sponsor
- Precisio Biotix Therapeutics
Names
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- bacteriophage cocktail of 14 phages against S. aureus, P. aeruginosa and K. pneumoniae
- Replication
- replicating
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04323475 | Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients | Unknown | Phase 1 | 2022-01 | 2023-01 | 12 | Wound Infection |
Recent changes
No changes recorded in its trials yet.
Notes
Phage cocktail sprayed on second-degree burn wounds; phase 1 NCT04323475, where it is called both 'phage cocktail-SPK' and PGX-0100. Separate from BACTELIDE, the same company's pressure-injury product. The registration gives a 14-phage cocktail at 1.4 x 10^8 PFU/mL and names S. aureus, P. aeruginosa and K. pneumoniae as the organisms it is meant to keep out of the wound.
How to cite
PGX-0100 (AXP000239.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000239.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.